Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Kala Pharmaceuticals, Inc. | kala-20201231xex32d2.htm |
| EX-32.1 - EX-32.1 - Kala Pharmaceuticals, Inc. | kala-20201231xex32d1.htm |
| EX-31.2 - EX-31.2 - Kala Pharmaceuticals, Inc. | kala-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - Kala Pharmaceuticals, Inc. | kala-20201231xex31d1.htm |
| EX-21.1 - EX-21.1 - Kala Pharmaceuticals, Inc. | kala-20201231xex21d1.htm |
| EX-10.31 - EX-10.31 - Kala Pharmaceuticals, Inc. | kala-20201231xex10d31.htm |
| EX-10.26 - EX-10.26 - Kala Pharmaceuticals, Inc. | kala-20201231xex10d26.htm |
| EX-4.2 - EX-4.2 - Kala Pharmaceuticals, Inc. | kala-20201231xex4d2.htm |
| 10-K - 10-K - Kala Pharmaceuticals, Inc. | kala-20201231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-226748 and 333-238087 on Form S-3 and Nos. 333-219403, 333-224083, 333-230206, 333-236402, and 333-239426 on Form S-8 of our report dated February 25, 2021, relating to the consolidated financial statements of Kala Pharmaceuticals, Inc. and its subsidiary appearing in the Annual Report on Form 10-K of Kala Pharmaceuticals, Inc. for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 25, 2021